N
Google TrendPOSICIONES DE ATLÉTICO DE MADRID CONTRA MANCHESTER UNITED (5000+) — Atlético 2 - 0 Manchester United: resumen, goles y resultado de la Champions League
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:posiciones de atlético de madrid contra manchester united5000+devils vs red wings2000+lioness season 35000+luis díaz200+halle berry child custody hearing200+lamine yamal5000+thélyson orélien500+abdulrahman alfozan500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Novo Challenges Lilly Wit" (30 stories)

Top Headline Story

Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data
Lead StoryYahoo Financegeneral
Sep 29

Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPWVRtMjBQTENVLWpnSXVkeHoyTVFFU0NKcEpDcHZObUVzMGIxNjc3WVdkTUpvNmxIS3NwM3hadzdIOFRoYmdmVkNoMnhseTVoOFVCV0FMbXp3cHZuWlAyal96aGJWOG1IalBkSnFCR2Z0UHAtd3Z5R3FtLWhiZW0xSHh3VW51OWlVQzJxODg3VUNGaDA0RGVlTGZWWnJRc3M?oc=5" target="_blank">Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
5000+19m ago

posiciones de atlético de madrid contra manchester united

Atlético 2 - 0 Manchester United: resumen, goles y resultado de la Champions League

Filter stories
2000+19m ago

devils vs red wings

Devils at Red Wings projected lineups

Filter stories
5000+19m ago

lioness season 3

Thank Zoe Saldaña for ‘Lioness’ Season 3’s Perfect Cliff-Hanger

Filter stories
200+29m ago

luis díaz

Max Eberl knows Luis Díaz will start scoring again for Bayern Munich

Filter stories

Search Results for "Novo Challenges Lilly Wit"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
TradingViewmarkets

Novo Down 11% in a Month: How Should Investors Approach the Stock Now?

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPUWhGTFdOdFZHdzRwM0NiRUs5TEFacmNqNUo0MGpGeE94eWo1Q2cwMHJjQ0lnc3JsQWpJSUhtZU9tamJHV1BtVmpVT29FbUpxVGZNQi1MdHlkLTlRMUdVSjNpN05lLXNMaU84Z0NtLU1HY2VSak5ZaWg3VzF4WjNmQ0w2NU9UUUJpSVZsSzB1NmUtRGQ4UDhxWC1ZWlczWHVlLUJHZVhzSWVMc3lza29UVFlXek50TEh5cktIcWgtVkE?oc=5" target="_blank">Novo Down 11% in a Month: How Should Investors Approach the Stock Now?</a>  <font color="#6f6f6f">TradingView</font>

Read Full StoryMore like this
What Pharmacists Should Know About Novo Nordisk-Eli Lilly GLP-1 Ad Suit
Pharmacy Timesgeneral

What Pharmacists Should Know About Novo Nordisk-Eli Lilly GLP-1 Ad Suit

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOWnVmVmU2UnF5MGIwUXBsUVdzQ2JkS1p4RE95T3FXcFpaMk5UQWdsR2ZRR0puS1hHYWpLMEsyU01kU19QcUk3V3NXMENaMDkyVnhVYUNYMzNDOEZHS2NqQkNKbnRZcXBRVUFMVThEaFo5NTJ4T2t6Ym9ET292X3RzSFdybG9GNURfMWZCam5qTE5ObjRkdE5fdGRXNzkyaThxTktfZWFienpMdw?oc=5" target="_blank">What Pharmacists Should Know About Novo Nordisk-Eli Lilly GLP-1 Ad Suit</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
Fierce Pharmageneral

Novo struggles to appease restive investors with consumer plans, blockbuster ambitions

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSk5RT3ItZHctNllUV29mamxnWHFPZVowN3Fncl9SYm4wWlVTWWxjSl9uYnoxRDFmYTdacWRkX185TGxQOWxxTjJuVk1HS3M5OXVyYWdUYk03V2ZiemRmdGU2V1p4YlJBLWduVDVXSk1jUFFhc0FvckYwd1JuU0FybnFvczU1NTZYdExBVlU5V0UzWmRlaXE2bkFWQW1ISV9VajNxOW1XRVJtYVk?oc=5" target="_blank">Novo struggles to appease restive investors with consumer plans, blockbuster ambitions</a>  <font color="#6f6f6f">Fierce Pharma</font>

Read Full StoryMore like this
How cost and perception could reshape the GLP-1 market
BioPharma Divemarkets

How cost and perception could reshape the GLP-1 market

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQdTVCYXBzbzBKMjRIMzdSYlNKQm1HcXB2NkJCQWJnQ043aDE2VTgzWDh0dGpncEpzRjJYbmk2ekpGaks2eFlVX2VtMHFBcUYtZzVRSWN5U3RlNGVCTUFzcUwyNC11cXdrMFdEdGQtT0FzMTRwWWRrWFJXVjgwMjZVbUV6UGQzUmpWS0daQQ?oc=5" target="_blank">How cost and perception could reshape the GLP-1 market</a>  <font color="#6f6f6f">BioPharma Dive</font>

Read Full StoryMore like this
Novo Undercuts Lilly With High-Dose Wegovy at $399 a Month
Bloomberg.comworld

Novo Undercuts Lilly With High-Dose Wegovy at $399 a Month

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOV1BJdjRGUkR6VHNaa3dMa1hNeHNVYWNqWWs1cTdkcFZlWWd6LXVBdXRrR05RSmp5WjZEUXhLMmpRSzkxWHQ0V0gtejNsMjlhZ2lqcmlXM0ZWTkpZbUVVc2swTEVvdWhvdFgwR3JtZW1iQ3A5dkpRVTJCU2xsSmlxeUxlSlhWWVBvX2pFMTVldTFfOE9qVzhqSlhqY0RibGQ5RnBLSUZQeXNHT3Rq?oc=5" target="_blank">Novo Undercuts Lilly With High-Dose Wegovy at $399 a Month</a>  <font color="#6f6f6f">Bloomberg.com</font>

Read Full StoryMore like this
Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
CNBCgeneral

Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxPX2pkcUZhbWVOQjVQU3l6MGx1OEc0Y29XMDRyMmw3b2VyWFMwV3RBYzJ1VWV0bHE5U0w5eGdCNTl3V1FDS1BDalFiRzR2Mm5WU2dWckVRQUVrTlpoTVR3VEw4TF85bjAxMUp1T2Zmb0stT25KLWNnNFIwS3RRdXZmdVlmU0RabjDSAYwBQVVfeXFMTkUwQUY3YnZHcTctQ3NWcjN1TFVUZjFYUXI4VDR0c2N6d1hUVXFHOXFMU0VnNjFJRklHQzhGSmhnX2dyVEExeFJrRl8wcmpEYjg4NTlScVRJTzg5bndjLUFFQnBhWkV6Rm5UQnlWRWY3VTlDcDJZNGdQbUVtTExLczVLLVdJemthSFdjRlo?oc=5" target="_blank">Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026</a>  <font color="#6f6f6f">CNBC</font>

Read Full StoryMore like this
Novo gains head start on Lilly with European Commission approval of Wegovy pill
Fierce Pharmatech

Novo gains head start on Lilly with European Commission approval of Wegovy pill

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNVlZkQWs1Y0FSWF9iLTlHTmp6ZnN0S3A1UFJFbkx3OTZ4ZTNaSXZKeGk5emYwaUJNV0RnN1VFSTIzX0lyTkRHV0lBYTdfWWdaYlZKajVxenpFZ2trdVVRYWF3dGQ5dmpWbE56TnU3M0VhczBrUlNHemdKY1VaRlBnZFJiSzZaVnc1NkhRSkl4bDF5TVVVTGVmbUwwNA?oc=5" target="_blank">Novo gains head start on Lilly with European Commission approval of Wegovy pill</a>  <font color="#6f6f6f">Fierce Pharma</font>

Read Full StoryMore like this
FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions
Manufacturing Chemistworld

FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPZDJmRWVNQzNZT1RWZDVULW54d0p1VlhFVmtBUDZxbjc3MmJZNFFsQjZJcFNzUGl4MFNmUmFjYXVMazVGenA1d3hIV1U0LWlxTGpWR3hFM2FZMmtYd2lCSGxnMFJVUFFhOE1NNTlKMXB4VDk0Mkp3YWVlM201b3MtbFg1X2lmX0xDMDFuZA?oc=5" target="_blank">FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions</a>  <font color="#6f6f6f">Manufacturing Chemist</font>

Read Full StoryMore like this
Novo Nordisk Files for Approval of Oral Weight-Loss Drug Wegovy in China, Challenging Eli Lilly's Lead
BigGo Financeworld

Novo Nordisk Files for Approval of Oral Weight-Loss Drug Wegovy in China, Challenging Eli Lilly's Lead

<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE9ueUticXh3TEppbHlKX1hTZTVMY1V3MTBORmlKblF1Zzd4aVE3ME9BMXYxQW9vbmU1V1A5Z1RoSWJGOWRkejloVnNIU0JrQkF0b1Z1SjFVaWRlWU1CQlJfdGpUMUVDRzNtY0tXaHp5anpUNGllRUE?oc=5" target="_blank">Novo Nordisk Files for Approval of Oral Weight-Loss Drug Wegovy in China, Challenging Eli Lilly's Lead</a>  <font color="#6f6f6f">BigGo Finance</font>

Read Full StoryMore like this
Novo Nordisk - Enough Is Enough: 5 Reasons It's Time To Sell (Rating Downgrade)
Seeking Alphageneral

Novo Nordisk - Enough Is Enough: 5 Reasons It's Time To Sell (Rating Downgrade)

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPMUt3eEN2aXcwbk1nUDBVQ015VmwzMXhfX3hfREV1OEdieHczOGRTNUo0UVBmX3NpMTZRZUktR1d0bm83YWJ4emxpQmNnNXVJZ05GRXVscFhqMDFtYkJCSEYtTkExa29FQ05ORDdiYkVSbGs5SzZrbUVEdjNMMUMxT25EbXYzZDRFb3l6d2FmTlU0UTVHVXU4SkJZbjB1RDBuWm1mSXZGdU1mQUxnTHNsbVJwX08?oc=5" target="_blank">Novo Nordisk - Enough Is Enough: 5 Reasons It's Time To Sell (Rating Downgrade)</a>  <font color="#6f6f6f">Seeking Alpha</font>

Read Full StoryMore like this
Roche Obesity Drug Enicepatide Delivers 22.7% Weight Loss in Mid-Stage Trial, Challenges Wegovy, Zepbound
Medical Dialoguesworld

Roche Obesity Drug Enicepatide Delivers 22.7% Weight Loss in Mid-Stage Trial, Challenges Wegovy, Zepbound

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxPeVU1V2l3VFZCMlAwWWh0dE83bE5MdzRnQWpyLU14N3BzRGpLVGlnd0YxZ3FWNEx6Zi1xTGd3LXFPNTBMVVRZT3dKZlpwR3dOcm4yZTFTZ0I5LVYzbHdLclJmVVdJVElsbU9NX0o1V1BVQUhCNXRMa0dMajczZ1RPalQ5SGhfVnkxNm80LTdJc3JDLXNwZF9OR19tZjZmbWFpYnoyUkxVNDBhR1VtZExHQzFpeXlSQXc3TWVOdkZuMlRxdDhUZUJMbFY5LS1GaWtXQVFJalFnYTFadFhISi10dDZFSFBkSkVXdk9fb0hn0gHzAUFVX3lxTFBQLXF5WU9fUlRMdUxNTC1HT3AzOHRfRkp6SFBaOHQwLTRnWVdVZHlCdGtISEtySmluRDF5UmJiMGV0YkZFc0hSOTcwc1R6Y19hOXU2c1JLMzFVUi00cGc1NHdsX1BSc2RWbTBhTktiUDlTbHVNVmJFV0JhelcxVGJEMllrS1E4cjFGdnJtOFRIemdvM0hHY2pjZ2VnWjFFZUZ4M1lkcVZzTVoxV0lPeWxhX1dTWjhJWHVnVjA1ampPSlM0ZnkweGpfYUxUS0traXhwS3VpalBPT1J0M3dJbnVxSGNPaHAzQ0FiLVZ6QWJ0TWtRTQ?oc=5" target="_blank">Roche Obesity Drug Enicepatide Delivers 22.7% Weight Loss in Mid-Stage Trial, Challenges Wegovy, Zepbound</a>  <font color="#6f6f6f">Medical Dialogues</font>

Read Full StoryMore like this
Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders
BioPharma Diveworld

Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOdDNIU0ZPa2x1MlkwY0RpTGZXQnBzMU8wNmZaQTJTLTZ1UWI4bVRpSjZoOGxkN0l2YVVhQnpXTG5nY3l4WVFZLWlyYUZhQUpaelFza25WWkotUi1PdGpOemlYc1NPTDlLcjhZU2NNS2pBTjBzeE04OE9jLWxDdnZ6R3c4UG1uUGc3TzlpSzBKSEcxTkxj?oc=5" target="_blank">Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders</a>  <font color="#6f6f6f">BioPharma Dive</font>

Read Full StoryMore like this
Eli Lilly: The Most Expensive Stock in Pharma; and Maybe the Best
TradingViewmarkets

Eli Lilly: The Most Expensive Stock in Pharma; and Maybe the Best

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPSlBDMlgxem1EX0xjUkhmd0xYUVBKNC1lU0c3YkFiT3M1SW8zOXhOOG4tR1YzY3Q4a0ItMzhPN29tWDdBdGdoanlfaXBFOWdSUFZVLTdkMFdraHdHOHhEdGpqU1FLcFlkQWxCckNGNm51dEFTdWx6QjVVNjNlYmVQU0syME1mTzdMdllfS2ZMMUF2ZjBlZmZ3Mmo1M1Y1TEpPWU9jMDRpRVUwaTJLMkRhVExNQ1Z0VnBFUHFOV3kxcDU?oc=5" target="_blank">Eli Lilly: The Most Expensive Stock in Pharma; and Maybe the Best</a>  <font color="#6f6f6f">TradingView</font>

Read Full StoryMore like this
India’s GLP-1 surge: domestic drugmakers challenge Novo and Lilly
The Pharma Lettergeneral

India’s GLP-1 surge: domestic drugmakers challenge Novo and Lilly

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxNeGZUZUsxdVhXN3pVMFE3ZXV5MHpxSmtqTzN4OGtlV3pwVUZRT1QxOUU3Q1NhRjRSZlotQ3A4YzlPUm9ZVndiX2lPNGM4QUg3TTk3LVUyTzg0VWNDSmZOMENiR1QxNEwwaVlXZ1FSbmFBY1pjbmVQY0l3cTI0WWxPQ2tfNVA1SzNXQ09lVDRETDB6Rmx5OFdUZGRGdTFTa3RyZTBKaEVQYl9CaEJ4THJBcQ?oc=5" target="_blank">India’s GLP-1 surge: domestic drugmakers challenge Novo and Lilly</a>  <font color="#6f6f6f">The Pharma Letter</font>

Read Full StoryMore like this
Novo Challenges Lilly With up to $2B Bet for Triple-G Obesity Drug From Chinese Biotech
BioSpacetech

Novo Challenges Lilly With up to $2B Bet for Triple-G Obesity Drug From Chinese Biotech

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPMHFfRVQ4ejZDdFAxbXVESG5BaC04ZjR5VXFPZWx2VjJoSHFkU0g0NW5uSUk1bHdENlVDcUFjZXE2dlR0ZVRqNHh6WUJHZUhvU05SM181Ti1Uc3piWHNlQkFPS0cycEI1bUU3RjRoRkNjMURVeHpVUWF2RVhzLXFTN3kxWEszLVdaS2MtU3dtVS1Cd1laV09pdXVFXzZCdlRCOGlJMndLam1Xc1RiY1BWZzRJSzM0TGV3MFVQSg?oc=5" target="_blank">Novo Challenges Lilly With up to $2B Bet for Triple-G Obesity Drug From Chinese Biotech</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Novo tops Pfizer with $6.5B bid for Metsera
BioPharma Divegeneral

Novo tops Pfizer with $6.5B bid for Metsera

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNb0FrTnF5MnhTNHFPNlV0MGV0eW9FNlRkQ2cxTkpKYldOc0hETFNReDQwaUlpZ0gwRFhwaUd4OEVoRUh5Nm1tVm5yTDhHbzlQY0xEZkVLZW9RSkFLTHB6dFpCWFhhVFVqVENOOWRncm9rcFVmOVp2OEQ3emRUUm8tZGZ5NVRBRHhLdTg0MjRJa1Iwdw?oc=5" target="_blank">Novo tops Pfizer with $6.5B bid for Metsera</a>  <font color="#6f6f6f">BioPharma Dive</font>

Read Full StoryMore like this
Lilly, battling skepticism, reinforces GLP-1 pill’s case with new study data
BioPharma Divegeneral

Lilly, battling skepticism, reinforces GLP-1 pill’s case with new study data

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNVjZxMUhNQXBWMFE0b3VKTXljajZaQ2kxTFFiWHlnVE10OVFqR2w5Wk5iSDJnVTB1S2hhMHFyM0V2bFc0d3g1T0pnVEwyMWVWWndIZTVDVVdublFhMXV5VUVlUXVkb1lPazlCQlV1NW1paFd3MXI4WFhlSUMxUUVzb1A5bGl3TFBHTllCWGNKLTlkY0FseVhN?oc=5" target="_blank">Lilly, battling skepticism, reinforces GLP-1 pill’s case with new study data</a>  <font color="#6f6f6f">BioPharma Dive</font>

Read Full StoryMore like this
Lilly’s triple-acting obesity drug hits goal in Phase 3 trial
BioPharma Divegeneral

Lilly’s triple-acting obesity drug hits goal in Phase 3 trial

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNNHA4ZHZEY0dtMUg3THNSekVWM0JHTl9fbzAtN3FCeDBiaHRUdmpOOTF2dHpHNkVFa2dUTkN4aS1GczBYaGJPOHMzd3pqZGVpa1p2eVAtbHY1cEZ0ck93aHJCWEpfdDhKT29kZkg3OWw1VDBld0hYZDJKX29YeXJ3cmxBR2Q0WlQ2X1JkQlJzb1RKdFU?oc=5" target="_blank">Lilly’s triple-acting obesity drug hits goal in Phase 3 trial</a>  <font color="#6f6f6f">BioPharma Dive</font>

Read Full StoryMore like this
Novo, Lilly cut deal with Trump to lower prices of obesity drugs
BioPharma Divegeneral

Novo, Lilly cut deal with Trump to lower prices of obesity drugs

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOMmRQT0dFZWFYenhNQXRPbFd1eUpPZnhJVWZselV4d2xZenBrYXAxYV9xcmpjOEJidHBVaWwxbW9FZVBkNDBybUZwMlFFb0pRR0tYNkFpeUYtcWpqQ1dtNG1ES1dMMnoxMlkzb2hRbktXTW8zTWFFNW5yLW9rZFlCTmdlT2ZGU0otVkpHek1TV081TXJfUFlreFMwOGNLQjRBd3BZ?oc=5" target="_blank">Novo, Lilly cut deal with Trump to lower prices of obesity drugs</a>  <font color="#6f6f6f">BioPharma Dive</font>

Read Full StoryMore like this
Eli Lilly’s key obesity pill falls short of rivals, but the company still beat on earnings
STATgeneral

Eli Lilly’s key obesity pill falls short of rivals, but the company still beat on earnings

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxQakxaa2JSYXJNajBkaElsRHpqWUVaSlhDNXo4UnpEbnR0cUc0ZEMwc3lZNmdBNXI5QmZpS29qaVN5Z2Itb2pGNm9BSmU1UlI1VVprUDFZQXQ4V3hnOUdmZWZMNmt4RGJlelMxb2hqc3lPYlFmY0p4cHk1cDlKLUhjV0FSX20?oc=5" target="_blank">Eli Lilly’s key obesity pill falls short of rivals, but the company still beat on earnings</a>  <font color="#6f6f6f">STAT</font>

Read Full StoryMore like this
Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy
CNBCgeneral

Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxNemVyQmlhME05bEdMR0c4eWxoTUwwMEphRkdVd0N1S09UZDlHRnBRbGpHeGpWVTFHdG92X0FPREdUSVZCRzNOVTNfVnhOZXVrQUlCeHpRdVIwbXBMc1NfdGRKR3dwaWEwWXlZUUNCdTB6TFZycXJSWWVSV1J6ZWMwQ3JadU9nMG5BTFVLTdIBkgFBVV95cUxOc0VQS2RieHMwT0dxZ1JoamF1QVFWOFh1T004SkdKaTlTdnJyMjhyakxGZlNBbDh1dmswbDluNVNieFdtdlBEWk1YNFJEZHFfVV9yLXVfZk1YUXRaVGg4d2pLTTh5Y1NhZlFkeXFVWmNKeUltanREaWpDWUZyUlNQNUdhZUdkWkJTSld1VzBzbm1WUQ?oc=5" target="_blank">Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy</a>  <font color="#6f6f6f">CNBC</font>

Read Full StoryMore like this
Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial
BioPharma Divegeneral

Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPVGhraW5YYm9BRlJFTjlyVWlBUk9CdzV1T2FjVFFfOTJMa25VNTdVb3h1b3E3cWtLVkROTG5iVUdBZURpQ1NjN1dCOGVCMVlhaVBRT1NtcEh3WnZqbWRvYTZNdE4yZkw1TVpjelFUQ2l2LXo4c2E1Z0I4NDVIZlA3MFVPaWZjNXY1ZGlpTzB0aHFzZnJvN1VJdDc0eHROSzFH?oc=5" target="_blank">Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial</a>  <font color="#6f6f6f">BioPharma Dive</font>

Read Full StoryMore like this
Chinese Biotech Takes Aim At Eli Lilly, Novo Nordisk With New GLP-1 Weight-Loss Drugs As Patent Clocks Tick
Stocktwitstech

Chinese Biotech Takes Aim At Eli Lilly, Novo Nordisk With New GLP-1 Weight-Loss Drugs As Patent Clocks Tick

<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxQTnhnWnBDV1FtekZnUE1LZUtFMmZkTE9XX2s1dTdLUXR4SFJreTEwd05lTXVvN3Q0bXdOQTMwVWVVdzdJa0N4bXA2WUF3MEJrNF9sdzFwdkRHdXFSVUlSZmxoWHc4Rm0zM3BlcmlZdE9rUENvLTVPaXNlakdBQzJVdFYxcmM5b2lVZVhhYURhX2tQU052MzdPMkhOcHpTMlc2VlBIMk5YRmtrWVFJeFF2UzRuSmUwTTZIWDYxUmY4SU1LSlBzZ1pqdHVSTi1jWUVmYmlfUnZOLUtweGpaRVVNT3duMno4bFd0aEpnMzRqanRkQjhjUVRka0dpLU9kVTA?oc=5" target="_blank">Chinese Biotech Takes Aim At Eli Lilly, Novo Nordisk With New GLP-1 Weight-Loss Drugs As Patent Clocks Tick</a>  <font color="#6f6f6f">Stocktwits</font>

Read Full StoryMore like this
With Vivtex deal, Novo gains a chance at better oral obesity drugs
BioPharma Divetech

With Vivtex deal, Novo gains a chance at better oral obesity drugs

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPLXFOc0NjQmRkNTU4dzNQZ3ptUjBKdkZ2VWdyN3h4ZnN0OEx4My03bEl1SndORU1BcnkxLTB3ZHFSUnV2UXBaT2NBR3A3TjYtZHNJZzZ6LVlFSDRraWNqNjZhcjYzcGpydndES3NDdUY2NERaTkFWeC1ybzBlMVFVbzVUNUtGS0g1SjZBeHB4NVJiUnpwSFE?oc=5" target="_blank">With Vivtex deal, Novo gains a chance at better oral obesity drugs</a>  <font color="#6f6f6f">BioPharma Dive</font>

Read Full StoryMore like this
Lilly aligns with Walmart in bid to broaden access to discounted Zepbound
BioPharma Diveworld

Lilly aligns with Walmart in bid to broaden access to discounted Zepbound

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNNVo4UmRsTllEOUE1M2tXY3RIemZIN210endvS0pCaUx6Uk9CaUlRZnM3d3RTX2kwYUtxNmsxSlQteXlSU3lBUWRWWm9RX0lwb2NXXy1xY2V5YU8wSjdoSkhGanJlM1JfYW1OS0tMRmVGWUVVcDRzVjBhcTdab2xQZi00UUxvVmZaR1V5cC1leUY?oc=5" target="_blank">Lilly aligns with Walmart in bid to broaden access to discounted Zepbound</a>  <font color="#6f6f6f">BioPharma Dive</font>

Read Full StoryMore like this
To Compete in Obesity, Late Entrants Invest Early in Manufacturing
BioSpacegeneral

To Compete in Obesity, Late Entrants Invest Early in Manufacturing

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNZEhQOG5nMjFKWmdIWEYxOGE5U3RGeWVIS3R1Z2ZFWlJnVHp6QTc0dFhoS3d3ck5DNnVXVVcxZGZjcmxXRzd6TWlJNVdxeUJldmFsXzlBQXdSemJ0Q1JSMG93MzVfeVhiQVlOLXFERWJ0UW1sQTFpYVJENEdsMm5XOXRTU0ZicEltTS1Ld0RiMlAxMHNJTkVIYkRCblAwaUtn?oc=5" target="_blank">To Compete in Obesity, Late Entrants Invest Early in Manufacturing</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial
BioPharma Diveworld

Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNdFc4MzhiS083aXZsMkFkellvVUg0WVBDX0ZuNUNZbVRfeVhiT3lheUEyVWt3WlZ0ZlFxSWJ4eGx4MkwwNlZLYko0MVBKM1ZOM1Q1MEl2VkpfanFSOURTUDZWT1lmTnBuOWNrLUp5QkJpbmhBVDFoZ0dISmxpS1UzSEQyWkRaR1BNMEVOd2lCOXFkMEg3LWl6SE4wVFZ0OFZzWEE?oc=5" target="_blank">Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial</a>  <font color="#6f6f6f">BioPharma Dive</font>

Read Full StoryMore like this
FDA approves GLP-1 weight loss pill Foundayo from Eli Lilly
NBC Newsworld

FDA approves GLP-1 weight loss pill Foundayo from Eli Lilly

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPbFd3dTVrVlJNNFVOVEZ4QTFRa3p4ZWs3ZEZaTTVhQ21vTWRCR2kwVEZMcEVUbGpTSDRCcGtsS2FqcmxWWDdHalI3WWFjZElDcm5TbFpOWTlaMDJPbXlBaUdTMlhQb2VhZXhFLXNMX2Z4TmhyS1ZEbGlWSmduRU1UTGtYWTNNUVlnWktEaGxjU1ZlTm1GQy0wZExncDJFQi1LWUp1M01TMTYwbzZwcXlkVzJHdw?oc=5" target="_blank">FDA approves GLP-1 weight loss pill Foundayo from Eli Lilly</a>  <font color="#6f6f6f">NBC News</font>

Read Full StoryMore like this
Compounders maintain a firm grip on the GLP-1 market
BioPharma Divetech

Compounders maintain a firm grip on the GLP-1 market

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPdVZkMEdnRnZjNjByWlBiR214WkVkU0lqaWJJbWhqYlpFazJaWUlmRVRNbXNlbk1vdllBZkNIOFh2Q1hfZXl0bnR5dzNTZzdPX2ZwZC1GcEhIV2xUYXI4RmV6NUtpa3l4cUJRRkhLempvT2prb3gzSFVIcjE3MkRkLUxJNmJDZVVLQ3E5Tm9oTVlLQQ?oc=5" target="_blank">Compounders maintain a firm grip on the GLP-1 market</a>  <font color="#6f6f6f">BioPharma Dive</font>

Read Full StoryMore like this
"Novo Challenges Lilly Wit" — Live Google News Trends & Headlines